New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:39 EDTARIAARIAD reports commercial availability of Iclusig for patients with RPP leukemias
ARIAD Pharmaceuticals announced the commercial availability of Iclusig for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
07:38 EDTARIAARIAD appoints DesRosier as Chief Legal and Administrative Officer
Subscribe for More Information
January 20, 2015
07:36 EDTARIAARIAD says EC endorses final opinion adopted by CHMP on Iclusig
Subscribe for More Information
January 14, 2015
07:20 EDTARIAARIAD sees product revenues reaching over $400M in 2018
For 2014, sees product and license revenue at $100M, R&D expenses $120M. For 2015, plans to accelerate Iclusig sales in U.S. and Europe, initiate key Iclusig trials, secure broad partnership for brigatinib, file for Iclusig approval in Japan with Otsuka, file IND for new development candidate AP32788. Comments from slides that will be presented at the JP Morgan Healthcare Conference.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use